Clinical trials: Geriatric Hematology
Aplastic Anemia
Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years
Outcomes for adult patients with Severe Aplastic Anemia (SAA) aged more than 40 years who are refractory or in relapse after first-line IST remain poor.
- Trial name
- APARR (NCT06646497)
- Testing
- Allogeneic hematopoietic stem cell transplantation Stem cell source only Bone Marrow
- Where
- 26 sites in France
- Volunteers
- 52 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Myeloid Leukemia
ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)
A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid (ATRA) in Combination with Induction Chemotherapy, or Azacitidine and Idarubicin as salvage therapy and Idarubicin with Cytarabine or…
- Trial name
- ALFA-0703 (NCT01067274)
- Testing
- Vesanoid (ATRA), AZACITIDINE (VIDAZA), CYTARABINE
- Where
- 26 sites in France
- Sponsor
- Acute Leukemia French Association
Sickle Cell Disease
PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4)
The purpose of this Phase I study is to investigate the pharmacokinetic properties of ticagrelor in pediatric patients from 0 to less than 24 months with sickle cell disease.
- Trial name
- HESTIA4 (NCT03492931)
- Testing
- Ticagrelor
- Where
- 8 sites in Belgium, Italy and 4 more
- Volunteers
- 21 people
- Sponsor
- AstraZeneca
AML, Adult
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
This study is a multicenter, randomized, controlled phase III clinical trial aimed at comparing the efficacy of two induction chemotherapy regimens-VA (Venetoclax + Azacitidine) and D/IA (Daunorubicin/Idarubicin + Cytarabine)-in…
- Trial name
- NCT07132684
- Testing
- Daunorubicin/Idarubicin, Cytarabine, Azacitidine
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukemia, Myeloid, Myelodysplastic Syndromes
Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes
The goal of this clinical research study is to learn if the combination of Gleevec (imatinib mesylate) and low doses of Cytarabine (ara-C) may help to control leukemia while causing fewer side effects than standard high dose…
- Trial name
- NCT00451997
- Testing
- Gleevec, Ara-C
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS
To explore the efficacy and safety of prolonged low-dose decitabine (10 days of 6mg/m2) plus venetoclax (3 weeks/cycle) regimen in primary diagnosed elderly or frail AML/ high-risk MDS.
- Trial name
- NCT06046313
- Testing
- Decitabine for Injection, VENCLYXTO
- Where
- China
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Acute Myeloid Leukemia
A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old
The main objective of this study is to compare conventional chemotherapy: daunorubicin and the Aracytine and this chemotherapy in combination with the monoclonal antibody used Mylotarg in divided doses.
- Trial name
- NCT00927498
- Testing
- conventional chemotherapy (AraC + Daunorubicin),, Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),
- Where
- 19 sites in France
- Volunteers
- 280 people
- Sponsor
- Acute Leukemia French Association
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)
This is an open-label, non-randomised, multi-centre phase I-II study of CHR-2797 administered orally once a day. The study involves two distinct phases: Phase I: an open-label, dose-escalating phase of the study to explore the…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
- Trial name
- NCT00689000
- Testing
- CHR-2797 (tosedostat): Aminopeptidase inhibitor
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- Chroma Therapeutics
Anemia, Iron Deficiency
Impact of Dried Moringa Oleifera Leaves in Enhancing Hemoglobin Status
This research project is aimed at combating the nutritional deficiencies (Iron deficiency anemia) of reproductive aged females belonging to the underprivileged group of the society.
- Trial name
- NCT03514472
- Testing
- Dried Moringa oleifera leaves
- Volunteers
- 34 people
- Sponsor
- Kinnaird College for Women
Acute Myelogenous Leukemia
Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)
This Phase 1b study will determine the maximum tolerated dose of KX2-391 given as a once-daily dose, in elderly patients with acute myelogenous leukemia.
- Trial name
- NCT01397799
- Testing
- KX2-391
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Kinex Pharmaceuticals Inc.
Anemia
The Prevalence of Malaysian Children Aged ≥ 6 to ≤ 36 Months at Risk of Anaemia
The main purpose of this study is to determine the prevalence of Malaysian children aged ≥ 6 to ≤ 36 months at risk of anaemia by measuring Total Haemoglobin (SpHb) using a non-invasive haemoglobin assessment.
- Trial name
- NCT05181436
- Testing
- measuring Total Haemoglobin (SpHb) using Masimo Rad-67.
- Where
- Malaysia
- Volunteers
- 1,215 people, healthy volunteers welcome
- Sponsor
- Danone Specialized Nutrition (M) Sdn Bhd
Leukemia
AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia
RATIONALE: AT9283 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/IIa clinical trial is studying the side effects and best dose of AT9283 in treating young…
- Trial name
- NCT01431664
- Testing
- multikinase inhibitor AT9283, laboratory biomarker analysis, pharmacological study
- Where
- 5 sites in United Kingdom
- Volunteers
- 7 people
- Sponsor
- Cancer Research UK
Multiple Myeloma
Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone
This protocol is a single-arm, three-cohort, phase II multicenter study designed to assess the safety and the efficacy of three all-oral combinations: Velcade with continuous low-dose melphalan and prednisone (VMP) or with…
- Trial name
- NCT01190787
- Testing
- velcade subcutaneous melphalan prednisone, velcade cyclophosphamide prednisone, velcade prednisone
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- European Myeloma Network B.V.
Acute Myeloid Leukemia
D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients
With the aging of society, the incidence of elderly leukemia in China has been increasing year by year. The elderly patients with Acute Leukemia have poor basal state, and there are many important organ diseases such as heart…
- Trial name
- NCT04168138
- Testing
- rhTPO
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Huihan Wang
Acute Myeloid Leukemia
Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk
The main objective of the study is to improve outcome of younger patients (between 18-60 years) with acute myeloid leukemia and intermediate risk defined by the cytogenetics.
- Trial name
- LAM2006IR (NCT00860639)
- Testing
- gemtuzumab ozogamycin
- Where
- 29 sites in France
- Volunteers
- 327 people
- Sponsor
- Nantes University Hospital
Pediatric Cancer
Effects of Therapeutic Play on Anxiety and Fear
This study was carried out as a randomized controlled experimental study in order to evaluate the effect of therapeutic game use on anxiety and fear levels before indwelling catheter intervention in children aged 6-12 years…
- Trial name
- NCT06229327
- Testing
- THERAPEUTICGAMES
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Okan University
Acute Myeloid Leukemia
Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia
Patients aged ≥70 years with acute myeloid leukemia (AML) have a poorer prognosis than those aged 60 to 69 years. The poor outcome is the result of treatment-related toxicity in elderly patients, owing to comorbidities, the…
- Trial name
- NCT02844218
- Testing
- Age of patient
- Where
- France
- Volunteers
- 183 people
- Sponsor
- Hospices Civils de Lyon
Haemophilia, Autism Spectrum Disorder
Prevalence of Autistic Spectrum Disorder (ASD) in Children With Haemophilia
Parents of children with haemophilia will be invited to complete 3 questionnaires to look for traits present in ASD. With consent teacher will complete a further 2 questionnaires.
- Conditions
- Haemophilia, Autism Spectrum Disorder, Social Communication Disorder, Attention Deficit Hyperactivity Disorder
- Trial name
- NCT05138224
- Volunteers
- 82 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
Multiple Myeloma in Relapse
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Induction therapy approaches in recent years have evolved, now utilizing triple or quadruple drug regimens in the majority of patients.
- Trial name
- NCT06827860
- Testing
- Talquetamab, Daratumumab
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Larysa Sanchez
Acute Myeloid Leukemia, Adult
Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia
This prospective multicenter clinical study was designed to assess the efficacy and safety of decitabine in combination with low-dose cytarabine induction treatment for elderly patients with newly diagnosed acute myeloid leukemia…
- Trial name
- NCT02985372
- Testing
- Decitabine, Cytarabine
- Volunteers
- 30 people
- Sponsor
- Chunyan Ji